SCOTUS rules unanimously in favor of Sanofi and Regeneron in PCSK9 patent spat with Amgen
In a closely fought patent battle between PCSK9 rivals Amgen and Sanofi/Regeneron, the Supreme Court ruled unanimously on Thursday that Amgen cannot monopolize the market for any and every antibody that binds to areas of the sweet spot of PCSK9.
The win for Sanofi and Regeneron is a setback for companies like Amgen who are looking to patent broad categories of antibodies, but cannot produce each of the antibodies that might fall into such a category.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.